GC012F (AZD0120)

A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma

What's the purpose of the trial?

This trial is a phase 1, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CAR T-cell therapy, in early-line treatment in subjects with Multiple Myeloma.
Trial status

Accepting patients

Phase
Phase 1
Enrollment
18
Last Updated
2 days ago

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • AZD0120 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize BCMA (a protein found on myeloma cells) more easily.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.